AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02894645
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous
Trial: NCT00857675
Drug: AAAA
RxNorm normalized name: I do not have enough information to determine the full generic name for the drug abbreviation 'AAAA'. Drug abbreviations can vary and may not have a standardized full generic name. Without more context about the specific drug or clinical trial data, I cannot provide the full generic name. I apologize that I cannot give you a more definitive answer.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adefovir Dipivoxil (12 weeks) + open lable Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260weeks)
Trial: NCT01585415
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
Trial: NCT00865228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.
Trial: NCT00449865
Drug: creatine
RxNorm normalized name: Creatine
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Creatine, a widely used dietary supplement is thought to improve exercise performance. In animal models and human studies, creatine has been shown to be well tolerated and may have some ability to protect brain cells.~The study is comparing creatine 5 grams twice daily with placebo.
Trial: NCT02626026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules administered orally.
Trial: NCT02356588
Drug: Sufentanil Tablet 30 mcg
RxNorm normalized name: sufentanil Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02356588
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01507792
Drug: iron sulphate
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 or 2 330 mg/daily iron sulphate oral tablets
Trial: NCT02479451
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study medication will be provided by Foundation Care.
Trial: NCT04018131
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug
Trial: NCT00381862
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: as per institutional standard of care
Trial: NCT00381862
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: as per institutional standard of care
Trial: NCT00375973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill dose comparable to duloxetine
Trial: NCT00891020
Drug: Nonbiologic DMARDs of investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonbiologic disease-modifying antirheumatic drugs (DMARDs) As prescribed
Trial: NCT01691560
Drug: 5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
Trial: NCT01691560
Drug: 0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
Trial: NCT01544985
Drug: placebo po
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile water
Trial: NCT03574285
Drug: Anpl-one SR Tab. 300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
Trial: NCT03574285
Drug: Sarpodipil SR Tab. 300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
Trial: NCT04297748
Drug: M7824
RxNorm normalized name: M7824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifunctional fusion protein intended to block PD-L1 and neutralize TGFbeta simultaneously.
Trial: NCT04557215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied.
Trial: NCT02087540
Drug: Rosuvastatin 20mg
RxNorm normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02087540
Drug: Rosuvastatin 10mg
RxNorm normalized name: ROSUVASTATIN 10MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02087540
Drug: Placebo(for Rosuvastatin 20mg)
RxNorm normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02087540
Drug: Placebo(for Rosuvastatin 10mg)
RxNorm normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00326274
Drug: Helioblock® SX Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03038867
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally 2 tabs daily for 5 weeks, then taper to 1 tab daily for 1 week
Trial: NCT00427648
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline
Trial: NCT04351919
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg per day during 5 days
Trial: NCT02182115
Drug: standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgeon's instructions may include advising patients to use an antiseptic soap prior to surgery.
Trial: NCT00380133
Drug: SB681323
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg and 2.5 mg tablets - The tablets will be round (9.0 mm in diameter) and white and provided in labelled bottles
Trial: NCT00380133
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg size DB AA capsule shell (Swedish orange) with a powder backfill (lactose Anhydrous)
Trial: NCT00380133
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets matched to SB681323 or prednisolone
Trial: NCT04282941
Drug: Ibuprofen in continuous (24 hours) iv infusion and EchoG
RxNorm normalized name: hydrocodone and ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first dose of ibuprofen will be 10 mg / kg to be administered as a continuous infusion for 24 hours. An echocardiogram will be performed before each of the following 2 doses of 5 mg / Kg and will only be administered if it meets echocardiographic criteria that indicate open DA (observation of ductus permeability with color Doppler regardless of its size). Each dose will be administered as a 24-hour continuous infusion.
Trial: NCT04282941
Drug: IV bolus Ibuprofen slow (15 minutes) and EchoG
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first dose of ibuprofen of 10 mg / Kg to be administered in slow iv bolus (15 minutes). Before each of the following 2 doses of 5 mg / Kg, echocardiography will be performed and will only be administered if it meets the echocardiographic criteria indicated by open DA (observation of ductus permeability in color Doppler regardless of its size). Each dose will be administered in iv boluses in 15 minutes
Trial: NCT04415164
Drug: Xueshuantong lyophilized powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xueshuantong lyophilized powder (500mg), diluted with 250 ml of 0.9% sodium chloride injection, IV (in the vein), once a day, continue for 10 days.
Trial: NCT04415164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xueshuantong lyophilized powder Placebo. The usage of placebo is the same as that in the experimental group.
Trial: NCT02637206
Drug: GSK2894512 Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2894512 cream supplied will be white to off-white cream packaged in 28-gram laminate tubes of 2 concentrations: 0.5% and 1%, to be applied topically.
Trial: NCT02637206
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Cream (placebo cream without active ingredient) supplied will be white to off-white cream packaged in 28-gram laminate tubes, to be applied topically.
Trial: NCT02637206
Drug: Empty Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empty patches without any ingredients will be used as negative control.
Trial: NCT02045069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 3 days
Trial: NCT02824055
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matched to RO5545965 capsules orally daily in any of the three intervention period.
Trial: NCT02824055
Drug: RO5545965
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive RO5545965 5 mg capsules or RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily in any of the three intervention period.
Trial: NCT00348777
Drug: thermal cure
RxNorm normalized name: Cocci-Cure C for Calves
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
Trial: NCT03019237
Drug: anti-IgE
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal anti-IgE
Trial: NCT02174510
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00372008
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003835
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00003835
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03059017
Drug: Niosomes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niosomes
Trial: NCT02220738
Drug: ABT-957
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-957 administered twice-daily for 7 days
Trial: NCT00131612
Drug: FEC 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluoruracil, epirubicin and cyclophosphamide every three weeks for six treatments
Trial: NCT00030901
Drug: L-selenomethionine
RxNorm normalized name: L-Selenomethionine Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization between active L-selenomethionine and placebo
Trial: NCT00030901
Drug: L-selenomethionine placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization between active L-selenomethionine and placebo
Trial: NCT03102996
Drug: Nephrotrans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hydrogen carbonate, ATC-Code: A02AH
Trial: NCT02418182
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen total dose of 1000mg
Trial: NCT02418182
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects randomized to this group will be given placebo tablets
Trial: NCT00764660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT00925951
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 500 mg tablets will be offered to both of the wet cupping group and waiting group for relieving severe pain.
Trial: NCT03821454
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral capecitabine (at a dose of 1250 mg per square meter of body-surface area, twice per day, on days 1 to 14) every 3 weeks for eight cycles.
Trial: NCT03821454
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebos (twice per day, on days 1 to 14) every 3 weeks for eight cycles.
Trial: NCT02612623
Drug: Placebo (for gefapixant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to gefapixant tablets administered by mouth twice daily for 8 weeks
Trial: NCT00191477
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)
Trial: NCT01218880
Drug: M2ES 7.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M2ES Dosage：7.5mg/m2
Trial: NCT01218880
Drug: M2ES 15mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M2ES Dosage：15mg/m2
Trial: NCT01593644
Drug: adenosine + dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: adenosine / dipyridamole combination given intravenously as a slow bolus at low doses
Trial: NCT00090025
Drug: 5-Fluorouracil Plus Leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-Fluorouracil (5-FU) + Leucovorin (LV) Dose: 375 mg /m2/day + 25 mg/m2/day Mode of administration: i.v. via central venous catheter or alternative i.v. administration.Duration of treatment: Days 1 through 5 of a 28 day cycle
Trial: NCT00630825
Drug: LY2189265
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00630825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01228734
Drug: 5Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU as a bolus of 400 mg/m\^2/day intravenously over 2-4 minutes followed by 600 mg/m\^2/day infusion over 22 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
Trial: NCT02042014
Drug: QTI571
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QTI571 200mg up to 400mg (depending on tolerability) taken orally, once a day.
Trial: NCT02478424
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01396135
Drug: CP-601,927
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 1 mg CP-601,927 given as oral 1 mg tablets
Trial: NCT01396135
Drug: CP-601,927
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of CP-601,927 given as 2 mg BID (4 mg/day) as oral 1 mg tablets for 7 days
Trial: NCT01396135
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of placebo given as a matching number of oral tablets
Trial: NCT00777296
Drug: ARIKACE™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study start date is before Jan 18, 2017.
Trial: NCT00777296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study start date is before Jan 18, 2017.
Trial: NCT02569970
Drug: fluoxetine 20 mg
RxNorm normalized name: fluoxetine 20 MG
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label.
Trial: NCT02569970
Drug: placebo 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label.
Trial: NCT00092118
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one placebo tablet, taken once daily at bed time for 6 weeks
Trial: NCT01631539
Drug: 5 FU
RxNorm normalized name: i5 Functional Food Nutritional Powder for Suspension (Vanilla Delight)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: every 2 weeks IV
Trial: NCT01464593
Drug: Lyso-Thermosensitive Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermally sensitive liposomal doxorubicin 50 mg/m2 single 30 minute intravenous infusion.
Trial: NCT01464593
Drug: ThermoDox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ThermoDox is a Lyso-thermosensitive Liposomal Doxorubicin designed to be used in conjunction with thermal ablation.
Trial: NCT03569930
Drug: flavonoid-based supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingredients: soybean oil (glycine max), edible gelatin, rutin, borage seed oil (borago officinalis), pineapple dry extract (ananas sativus), glycerol, thickeners (mono and diglycerides of fatty acids), emulsifier (soy lecithin).
Trial: NCT00672724
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon placebo-matching tablets, taken orally, once daily for up to 2 weeks.
Trial: NCT02888041
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.
Trial: NCT01908075
Drug: FP/SAL
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01908075
Drug: BDP/FOR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01288937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly assigned to placebo for 9 weeks (including a 1 week dose titration period), matching the schedule of the study drug.
Trial: NCT00879905
Drug: HSP990
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00775229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pill, by mouth, daily
Trial: NCT00386360
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral weekly for one year
Trial: NCT03458481
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg tablet administered orally once daily
Trial: NCT03458481
Drug: DAG181
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule administered orally once daily
Trial: NCT02647190
Drug: Erwinia Chrysanthemi asparaginase
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01419392
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, 4 times per day for 21 days
Trial: NCT05623540
Drug: Bisphosphonates, Combinations
RxNorm normalized name: Bisphosphonates, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00616148
Drug: YKP3089
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosage form
Trial: NCT00616148
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03390972
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (NaCl 0.9%) TCI infusion
Trial: NCT01560234
Drug: AZD8848
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, oral inhalation (nebuliser solution)
Trial: NCT01560234
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, oral inhalation (nebuliser solution)
Trial: NCT00264719
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 10 mg
Trial: NCT02069041
Drug: FOLFOX4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT00080756
Drug: therapeutic testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.275mg/100ul per day as a nasal spray
Trial: NCT00439283
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06181188
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients randomized to the midazolam and fentanyl arm will receive 25mcg incremental doses for procedural sedation
Trial: NCT01006122
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving placebo will undergo the same procedures as those receiving active treatment. Each patient will receive matching placebo tablets in a fixed dose escalation schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at 1.0 mg; decrease to 0.5 mg or increase to 2.0 mg based upon the clinicians judgment regarding efficacy and side effects at the 1.0 dose level. The patient will then remain at the determined dose for a 3 week stable dosing period, with a 7 (-2/+ 9) day wash out and then crossover to repeat the same sequence for the second arm of the study.
Trial: NCT01431716
Drug: EFI/ACT-385781A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002943
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03493854
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 600 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of ddAC Q2W or AC Q3W) for Cycles 1-4.